Brian and Barbara Pratt disclose 12.5% NeuroOne stake (NASDAQ: NMTC)

Rhea-AI Filing Summary

Brian and Barbara Pratt report beneficial ownership of 1,085,934 shares of NeuroOne Medical Technologies Corporation common stock, representing 12.5% of the company’s outstanding common shares. All shares are held in a joint account with a spouse, giving each shared voting and shared dispositive power and no sole authority.

The 12.5% interest is calculated using 8,702,982 NeuroOne common shares outstanding as of June 10, 2026, as referenced from a recent company report. Brian and Barbara Pratt have entered into a Joint Filing Agreement dated April 21, 2026, to report this ownership together.

Key Figures

Shares beneficially owned: 1,085,934 shares Percent of class owned: 12.5% Shares outstanding: 8,702,982 shares +3 more

6 metrics

Shares beneficially owned 1,085,934 shares NeuroOne common stock held in a joint account by Brian and Barbara Pratt

Percent of class owned 12.5% Portion of NeuroOne common stock class beneficially owned by the Pratts

Shares outstanding 8,702,982 shares NeuroOne common shares outstanding as of June 10, 2026 used for ownership calculation

Sole voting power 0 shares Shares over which each of Brian and Barbara Pratt has sole voting power

Shared voting power 1,085,934 shares Shares over which the Pratts have shared power to vote or direct the vote

Shared dispositive power 1,085,934 shares Shares over which the Pratts share power to dispose or direct disposition

Key Terms

beneficially owned, shared voting power, shared dispositive power, Joint Filing Agreement, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: The information set forth on the cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 1,085,934.00 7 | Sole Dispositive Power 0.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 1,085,934.00 9 1,085,934.00"

Joint Filing Agreement regulatory

"Exhibit Information Joint Filing Agreement, dated as of April 21, 2026"

title of class of securities regulatory

"Title of class of securities: Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 04:31 PM Accepted by SEC EDGAR 07/14/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What stake in NeuroOne (NMTC) do Brian and Barbara Pratt report?

Brian and Barbara Pratt report beneficial ownership of 1,085,934 NeuroOne common shares, representing 12.5% of the company’s outstanding stock. Their interest is based on 8,702,982 shares outstanding as of June 10, 2026, and is held in a joint account with a spouse.

How many NeuroOne (NMTC) shares were outstanding for the Pratt ownership calculation?

The reported 12.5% ownership is calculated using 8,702,982 NeuroOne common shares outstanding as of June 10, 2026. This share count comes from an amended quarterly report and serves as the reference base for determining the Pratts’ percentage of the company’s common stock.

Do Brian and Barbara Pratt have sole or shared voting power over their NMTC shares?

Brian and Barbara Pratt report 0 shares with sole voting power and 1,085,934 shares with shared voting power. They also have shared dispositive power over the same 1,085,934 shares, reflecting that all reported NeuroOne common stock is held in a joint account.

Where are Brian and Barbara Pratt based in the NeuroOne (NMTC) ownership disclosure?

Brian and Barbara Pratt list their principal business office at 5950 Berkshire Lane, Ste. 800, Dallas, Texas 75225. NeuroOne Medical Technologies Corporation’s principal executive offices are at 7599 Anagram Drive, Eden Prairie, MN 55344, providing geographic context for both the investors and the issuer.

What agreement governs Brian and Barbara Pratt’s joint reporting of NMTC shares?

Brian and Barbara Pratt are parties to a Joint Filing Agreement dated April 21, 2026. This agreement allows them to report their NeuroOne common stock holdings together as Reporting Persons, clarifying that their 1,085,934 shares and related voting and dispositive powers are disclosed on a coordinated basis.

How is beneficial ownership structured for the Pratts’ NeuroOne (NMTC) position?

The Pratts’ 1,085,934 NeuroOne common shares are held in a joint account with a spouse. Each reports no sole voting or dispositive power and instead reports shared voting and shared dispositive power over all these shares, reflecting joint control over the position’s key rights.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

NeuroOne Medical Technologies Corporation

(Name of Issuer)

Common Stock

(Title of Class of Securities)

64130M308

(CUSIP Number)

07/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 64130M308

1

Names of Reporting Persons

Brian Pratt

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,085,934.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,085,934.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,085,934.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 1,085,934 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Brian Pratt's spouse. The percentage in box 11 is based on 8,702,982 shares of Common Stock outstanding as of June 10, 2026, as reported in Amendment No. 1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 12, 2026.

SCHEDULE 13G

CUSIP Number(s): 64130M308

1

Names of Reporting Persons

Barbara Pratt

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,085,934.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,085,934.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,085,934.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 1,085,934 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Barbara Pratt's spouse. The percentage in box 11 is based on 8,702,982 shares of Common Stock outstanding as of June 10, 2026, as reported in Amendment No. 1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 12, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NeuroOne Medical Technologies Corporation
(b)	Address of issuer's principal executive offices: 7599 Anagram Drive, Eden Prairie, MN 55344
Item 2.
(a)	Name of person filing: Brian Pratt; and Barbara Pratt
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each Reporting Person is 5950 Berkshire Lane, Ste. 800, Dallas, Texas 75225.
(c)	Citizenship: Each Reporting Person is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 64130M308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
(b)	Percent of class: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Brian Pratt

Signature:	/s/ Brian Pratt
Name/Title:	Brian Pratt
Date:	07/14/2026

Barbara Pratt

Signature:	/s/ Barbara Pratt
Name/Title:	Barbara Pratt
Date:	07/14/2026

Exhibit Information

Joint Filing Agreement, dated as of April 21, 2026, by and between the Reporting Persons, attached hereto.